Download PDF
CC BY-NC-ND 4.0 · Facial Plast Surg 2021; 37(05): 673-680
DOI: 10.1055/s-0041-1726464
Original Research

Bioabsorbable Implant for Treatment of Nasal Valve Collapse with or without Concomitant Procedures

Douglas M. Sidle
1   Department of Otolaryngology—Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois
,
Pablo Stolovitzky
2   Department of Otolaryngology, Emory University School of Medicine, Atlanta, Georgia
,
Ellen M. O'Malley 
3   ENT Clinical Affairs, Stryker Corp, Plymouth, Minnesota
,
Randall A. Ow
4   Sacramento Ear Nose and Throat Medical and Surgical Group, Roseville, California
,
Nathan E. Nachlas
5   Ear, Nose, Throat, and Allergy Associates of Florida, Boca Raton, Florida
,
Stacey Silvers
6   Madison ENT and Facial Plastic Surgery, New York, New York
› Author Affiliations Funding This study was supported by Spirox (now part of Stryker).
› Further Information
   Permissions and Reprints

Abstract

The aim of the study is to report outcomes after treatment of nasal valve collapse with a bioabsorbable nasal implant. It involves two prospective, multicenter, post-market studies evaluating long-term effectiveness of the LATERA implant for severe to extreme nasal obstruction. Participants underwent implant alone or with concomitant inferior turbinate reduction (ITR) and/or septoplasty. Outcome measures included the change from baseline Nasal Obstruction Symptom Evaluation (NOSE) scores, NOSE responder rates, visual analog scale (VAS) scores, and adverse events. A total cohort of 277 participants (109 implants only, 67 implants + ITR, 101 implants + septoplasty + ITR) enrolled at 19 U.S. centers was available for analysis with 177 participants (69 implants only, 39 implants + ITR, 69 implants + septoplasty + ITR) available at 2 years. The mean changes from baseline in NOSE scores and VAS scores were statistically significant (p < 0.001) at all follow-up periods. The baseline NOSE score of 77.8 ± 13.6 was improved to 24.2 ± 23.6 at 24 months. Greater than 90% of participants were NOSE responders across all follow-up periods, 6.1% withdrew for lack of treatment effect. The baseline VAS score of 66.7 ± 18.8 was improved to 21.1 ± 23.9 at 24 months. There were no serious adverse events related to the device or implant procedure. Implant retrieval rate was 4.0% (22/543 implants). Nonserious adverse events were mild to moderate in severity, typically occurred within 6 months of implant, and resolved or were stable. Significant reductions in NOSE and VAS scores and high responder rates from our large population of patients with nasal obstruction who had nasal valve implants confirm sustained effectiveness at 24 months after treatment. The studies are registered on www.clinicaltrials.gov (NCT02952313 and NCT02964312).

Keywords

nasal valve collapse - nasal airway obstruction - bioabsorbable implant - lateral wall insufficiency - nasal valve repair


Publication History

Article published online:
14 April 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Rhee JS, Book DT, Burzynski M, Smith TL. Quality of life assessment in nasal airway obstruction. Laryngoscope 2003; 113 (07) 1118-1122
    CrossrefPubMedGoogle Scholar
  • 2 Clark DW, Del Signore AG, Raithatha R, Senior BA. Nasal airway obstruction: prevalence and anatomic contributors. Ear Nose Throat J 2018; 97 (06) 173-176
    CrossrefPubMedGoogle Scholar
  • 3 Chambers KJ, Horstkotte KA, Shanley K, Lindsay RW. Evaluation of improvement in nasal obstruction following nasal valve correction in patients with a history of failed septoplasty. JAMA Facial Plast Surg 2015; 17 (05) 347-350
    CrossrefPubMedGoogle Scholar
  • 4 Spirox, Inc.. 510(k) Summary – K161191. Created Jun 23, 2016. Accessed November 5, 2020 at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K161191
    Google Scholar
  • 5 Samra S, Steitz JT, Hajnas N, Toriumi DM. Surgical management of nasal valve collapse. Otolaryngol Clin North Am 2018; 51 (05) 929-944
    CrossrefPubMedGoogle Scholar
  • 6 San Nicoló M, Stelter K, Sadick H, Bas M, Berghaus A. Absorbable implant to treat nasal valve collapse. Facial Plast Surg 2017; 33 (02) 233-240
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Stolovitzky P, Sidle DM, Ow RA, Nachlas NE, Most SP. A prospective study for treatment of nasal valve collapse due to lateral wall insufficiency: outcomes using a bioabsorbable implant. Laryngoscope 2018; 128 (11) 2483-2489
    CrossrefPubMedGoogle Scholar
  • 8 Sidle DM, Stolovitzky P, Ow RA. et al. Twelve-month outcomes of a bioabsorbable implant for in-office treatment of dynamic nasal valve collapse. Laryngoscope 2020; 130 (05) 1132-1137
    CrossrefPubMedGoogle Scholar
  • 9 San Nicoló M, Stelter K, Sadick H, Bas M, Berghaus A. A 2-year follow-up study of an absorbable implant to treat nasal valve collapse. Facial Plast Surg 2018; 34 (05) 545-550
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Stewart MG, Witsell DL, Smith TL, Weaver EM, Yueh B, Hannley MT. Development and validation of the Nasal Obstruction Symptom Evaluation (NOSE) scale. Otolaryngol Head Neck Surg 2004; 130 (02) 157-163
    CrossrefPubMedGoogle Scholar
  • 11 Lipan MJ, Most SP. Development of a severity classification system for subjective nasal obstruction. JAMA Facial Plast Surg 2013; 15 (05) 358-361
    CrossrefPubMedGoogle Scholar
  • 12 Rhee JS, Sullivan CD, Frank DO, Kimbell JS, Garcia GJM. A systematic review of patient-reported nasal obstruction scores: defining normative and symptomatic ranges in surgical patients. JAMA Facial Plast Surg 2014; 16 (03) 219-225
    CrossrefPubMedGoogle Scholar
  • 13 Rippy MK, Baron S, Rosenthal M, Senior BA. Evaluation of absorbable PLA nasal implants in an ovine model. Laryngoscope Investig Otolaryngol 2018; 3 (03) 156-161
    Google Scholar
  • 14 LATERA ® absorbable nasal implant system. Instructions for Use. . Stryker; Doc# 4485–001-rB, November 2019
    Google Scholar
  • 15 Stolovitzky P, Senior B, Ow RA, Mehendale N, Bikhazi N, Sidle DM. Assessment of bioabsorbable implant treatment for nasal valve collapse compared to a sham group: a randomized control trial. Int Forum Allergy Rhinol 2019; 9 (08) 850-856
    CrossrefPubMedGoogle Scholar